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Abstract
Background: Malaria, an Anopheles-borne parasitic disease, remains a major global health problem causing illness and
death that disproportionately affects developing countries. Despite the incidence of malaria, which remains one of the most
severe infections of human populations, there is no licensed vaccine against this life-threatening disease. In this context, we
decided to explore the expression of Plasmodium vaccine antigens fused to the granule bound starch synthase (GBSS), the
major protein associated to the starch matrix in all starch-accumulating plants and algae such as Chlamydomonas reinhardtii.
Methods and Findings: We describe the development of genetically engineered starch granules containing plasmodial
vaccine candidate antigens produced in the unicellular green algae Chlamydomonas reinhardtii. We show that the C-
terminal domains of proteins from the rodent Plasmodium species, Plasmodium berghei Apical Major Antigen AMA1, or
Major Surface Protein MSP1 fused to the algal granule bound starch synthase (GBSS) are efficiently expressed and bound to
the polysaccharide matrix. Mice were either immunized intraperitoneally with the engineered starch particles and Freund
adjuvant, or fed with the engineered particles co-delivered with the mucosal adjuvant, and challenged intraperitoneally
with a lethal inoculum of P. Berghei. Both experimental strategies led to a significantly reduced parasitemia with an
extension of life span including complete cure for intraperitoneal delivery as assessed by negative blood thin smears. In the
case of the starch bound P. falciparum GBSS-MSP1 fusion protein, the immune sera or purified immunoglobulin G of mice
immunized with the corresponding starch strongly inhibited in vitro the intra-erythrocytic asexual development of the most
human deadly plasmodial species.
Conclusion: This novel system paves the way for the production of clinically relevant plasmodial antigens as algal starch-
based particles designated herein as amylosomes, demonstrating that efficient production of edible vaccines can be
genetically produced in Chlamydomonas.
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Introduction
Malaria is a mosquito-borne disease and remains a major global
health problem causing illness and death that disproportionately
affects developing countries. The worldwide incidence of malaria
is estimated by the Word Health Organization to be approxi-
mately 300 to 500 million clinical cases annually, with one million
deaths, the majority of which are young children [1–4]. Of
particular concern, the emergence of insecticide-resistant mosquito
vectors and multi-drug resistant parasites has contributed to
resurgences of the disease. Therefore, malaria control is a
continuous battle that requires long-term sustainability and
commitment. The development of a vaccine that reduces
morbidity and mortality would be a valuable new tool in the fight
against malaria. Plasmodium falciparum causes the most severe form
of the disease [5,6]. Infection begins when malaria sporozoites are
injected by mosquito into the host and within minutes parasites
invade hepatocytes, where they multiply and differentiate into the
next stage. The emerging merozoites invade red blood cells
leading to clinical illness [7]. The most advanced vaccine
candidate, designated RTS,S/AS02A, is based on the major
sporozoite surface antigen. However, this candidate vaccine,
currently in Phase 3 clinical trials, has shown only 30–65%
efficiency in field studies [8] and a vaccine with higher levels of
protection is still sought. Over time, people living in malaria-
endemic areas develop immunity to clinical disease caused by P.
falciparum and IgG from immune adults has been shown to reduce
parasite density and clinical symptoms when administered to
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during the blood-stage of the life cycle are good candidates for
inclusion in a vaccine [12,13], as a blood-stage vaccine would
reduce or prevent severe illness and complications of the disease.
In this context, we decided to explore the expression of
Plasmodium vaccine antigens fused to the granule bound starch
synthase (GBSS), the major protein associated to the starch matrix
in all starch accumulating plants and algae [14,15]. Starch-bound
proteins are known to remain stable for years within the
polysaccharide matrix purified from plants and algae. Starch can
be easily purified from plants and algae by straightforward
sedimentation procedures that in some systems do not even
require centrifugation. In addition, cereal starch, with its role in
human and animal diets, represents an approved source for the
production of glucose for injection in humans. As a first approach
to the use of recombinant polysaccharide particles for vaccine
production, we focussed our efforts on the production of
transgenic starch from chloroplasts of the green algae Chlamydo-
monas reinhardtii. We chose this system because of the ease and
unparalleled speed with which constructs can be introduced and
proteins expressed and correctly targeted to the chloroplast and
polysaccharide granule. In addition, expression of recombinant
vaccine antigens into starch granules localized into the Chlamydo-
monas chloroplasts would avoid protein N-glycosylation, a post-
translational modification that seems to be generally absent in
Plasmodium falciparum. Moreover, starch metabolism has been
investigated in great detail in this system through genetic dissection
of mutants allowing optimization of starch granule protein content
and polysaccharide structure [16–18]. To evaluate this novel
system, we have chosen two well-studied Plasmodium vaccine
candidates, MSP1 [19,20] and AMA1 [21,22], which are thought
to be involved in invasion of human red blood cells. The
biosynthesis, purification, characterization, and immunologic
properties of starch-stored clinically relevant antigens produced
in Chlamydomonas reinhardtii chloroplast are described.
Results and Discussion
Genetic engineering of Chlamydomonas vectors
expressing transgenic starch bound plasmodial antigens
We constructed a Chlamydomonas expression vector containing
the gene encoding a GBSS protein carrying a deletion that yielded
a product truncated for 130 amino acids at the C-terminus
(Figure 1a and Figure S1 online). We have previously shown that
the absence of this C-terminal tail does not impair stability and
targeting into the chloroplast [15]. A synthetic gene that encoded
the 19 kDa C-terminal peptide of P. falciparum MSP1 (PfMSP1-19)
was designed taking into account the GC-rich codon bias of
Chlamydomonas (Figure S2). This synthetic gene was fused to the
truncated GBSS gene followed by the paromomycin resistance
gene for selection of algal transformants (Figure 1a). The
expression of GBSS-PfMSP1-19 fusion protein is under the control
of a strong chimeric rubisco RBCS2 and HSP70A promoter
(Figure 1a). The Chlamydomonas BafR1 mutant strain with a
complete gene deletion at the STA2 locus that encodes GBSS [18]
was transformed with the GBSS-PfMSP1-19 expression vector. The
transformants developed normally during vegetative growth and
were indistinguishable from wild type algae. Starch granules from
Figure 1. Anti-malaria vaccine strategy and antigen expression in C. reinhardtii. (a) Map of the vector used for C. reinhardtii transformation
and expression. The plasmid of 9.4 kb, designated pSG2, carries the genomic region of 3 kb containing all introns and exons necessary for coding the
C. reinhardtii granule bound starch synthase (GBSS). The XhoI and BamHI restriction sites at the end of the truncated GBSS gene have been utilized for
cloning in-frame cDNAs encoding the C-terminal domain of P. berghei major surface protein 1 (MSP1-19); P. berghei apical major antigen (AMA1-C) and
P. falciparum MSP1-19. Expression of Chlamydomonas GBSS-Plasmodium fusion protein is driven by a strong chimeric Rubisco RBCS2 and HSP70A
promoter. (b) High-level of GBSS-P. falciparum MSP1-19 protein expression in one representative Chlamydomonas transformant (P5) was obtained by
co-transformation of the BafR1 mutant strain lacking the GBSS gene. Samples representing 1 mg of purified starch after French press disruption and
Percoll-gradient centrifugation were resuspended in SDS-bmercaptoethanol loading buffer, separated by SDS-PAGE and stained by Coomassie blue.
Note that minor protein bands accidently trapped in the polysaccharide matrix are common to wild type WT, P5 and mutant BafR1 algae lacking the
GBSS gene. The starch protein extracts from WT and P5 algae were also blotted to nitrocellulose and incubated with rabbit polyclonal antibodies
specific to C. reinhardtii GBBS (c), or rabbit anti-P. falciparum MSP1-19 (d).The molecular weights of protein markers are given in kDa.
doi:10.1371/journal.pone.0015424.g001
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disruption followed by sedimentation and Percoll gradient
centrifugation. The starch bound proteins were analyzed on
SDS-PAGE and Coomassie blue staining. Out of twenty clones
analyzed in a pilot experiment, three Chlamydomonas transformants
strongly expressed the GBSS-PfMSP1-19 fusion, as determined by
their expected electrophoretic mobility. One positive Chlamydomo-
nas transformant, designated P5, showed levels of starch-associated
GBSS-PfMSP1-19 protein that are slightly higher than those of the
standard GBSS of wild type reference algae (Figure 1b, lanes P5
and WT). This increase of GBSS-PfMSP1-19 in transgenic algae
compared to the wild type GBSS is probably due to both the
chromosomal insertion site insertion and the strength of the
chimeric HSP70A/RbcS2 promoter used in this context. In
addition, the promoter of the construct might not respond in an
identical fashion to circadian clock control, which is known to
operate on the wild-type GBSS gene [23]. Western blots using
rabbit-specific polyclonal antibodies confirmed that the fusion
protein of P5 transgenic algae contains the Chlamydomonas starch
bound GBSS fused to the P. falciparum MSP1-19 antigen (Figure 1c
and 1d).
Demonstration that genetically engineered starch
particles stored malaria antigens inside the chloroplast of
Chlamydomonas
While we explored the expression of P. falciparum MSP1-19 in
Chlamydomonas, we also extended our system to production of other
malaria candidate vaccine antigens. AMA1 and MSP1 C-terminal
domains derived from P. berghei, designated GBSS-PbAMA1-C and
GBSS-PbMSP1-19 (Figure S2), were investigated in detail, as the
murine malaria parasite is frequently used for animal vaccine
formulation and testing. Chlamydomonas transformed with these
constructs were screened by visualising the starch bound proteins
among a sample of 20 to 200 transformants. The presence of
transgenic starch containing GBSS-PbAMA1-C and GBSS-
PbMSP1-19 was demonstrated by ultrastructural-immunogold
labelling using two positive algal clones and specific polyclonal
antibodies (Figure 2c and 2d). As expected, there was no gold-
staining observed by electron microscopy on the starch of wild
type algae (Figure 2a), while strongly positive starch granules
containing P. falciparum GBSS-PfMSP1-19 were detected in
transgenic algae (Figure 2b). The data suggest a stronger
accumulation of P. falciparum GBSS-PfMSP1-19 protein in the
transgenic algae (Figure 2b) compared to P. berghei GBSS-PbAMA
1-C and GBSS-PbMSP1-19 fusion proteins (Figure 2c and 2d). The
differences in levels of P. berghei GBSS-PbAMA 1-C and GBSS-
PbMSP1-19 fusion proteins relative to that of P. falciparum GBSS-
PfMSP1-19 are likely due mainly to the influence of random site
integration events in the chromosomes of transgenic Chlamydomo-
nas. Hence, all GBSS-Chlamydomonas transformants expressed the
starch-associated GBSS-parasite antigens in transgenic algae
chloroplasts, as illustrated by full-ultrastructural section (Figure
S3). Generally, a significant accumulation of GBSS-PfMSP 1-19,
GBSS-PbAMA1-C and GBSS-PbMSP1-19 was detected within the
starch sheath around the single chloroplast pyrenoid (P) (Figure 2b-
d and Figure S3), which defines a protein agglomerate of mostly
Figure 2. Malarial antigen accumulation in starch of transgenic C. reinhardtii. Pre-immune rabbit serum used as control shows no gold
particles either on starch grains or over the pyrenoid matrix (a). Transverse sections of transgenic algae visualized by electron microscopy and
immunogold labelling with rabbit polyclonal antibodies specific to P. falciparum MSP1-19 (b), P. berghei AMA1-C (c) and P. berghei MSP1-19 (d). Note the
presence of positive gold particles (black dots) on the starch grains (white) surrounding the pyrenoid matrix in the middle, which also contained a
significant amount of GBSS-parasite fusion protein. The bar represents 500 nm. The total starch-bound protein content of purified granules
containing wild type GBSS (e) was compared to those of GBSS-PfMSP1-19 (f), GBSS-PbAMA1-C (g) and GBSS-Pf MSP1-16 (h). One and two milligrams of
starch purified from transformants and wild type algae were analyzed by SDS-PAGE and stained by Coomassie blue. The molecular weights of three
protein markers are given in kDa.
doi:10.1371/journal.pone.0015424.g002
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the pyrenoid structure itself. The immunogold signal over the
pyrenoid was not detected in untransformed controls (Figure 2a),
suggesting the presence of small fragments of transgenic starch
granules surrounding the pyrenoid. The total recombinant GBSS-
parasite fusion protein content was determined in all transgenic
transformants after starch purification. The highest concentrations
were confirmed in starch-associated GBSS-PfMSP1-19 (Figure 2f),
demonstrating the presence of higher levels of starch-bound
protein in the strains expressing GBSS-PfMSP1-19 in comparison
to those expressing wild type GBSS alone (Figure 2e), GBSS-
PbAMA1-C (Figure 2g), or GBSS-PbMSP1_19 (Figure 2h). These
results indicate that levels of starch associated GBSS-parasite
fusion protein estimated at about 0.2 to 1.0 mg of protein per
1.0 mg of purified starch can be obtained, validating the usefulness
of C. reinhardtii as an expression platform for complex recombinant
parasite proteins within starch granules.
Transgenic starch-bound antigens elicit immune
responses and protection against P. berghei challenge
To investigate whether the levels of transgenic starch-parasite
antigens achieved were sufficient to elicit protective immune
Figure 3. Starch-bound antigens elicit protection against P. berghei challenge. All mice survival experiments were performed using a group
of 10 Balb/c mice. (a) Life expectancy of a group of mice vaccinated after a single, or three doses of starch containing GBSS-PbAMA1-C. Each dose
contains 10 mg of purified starch derived GBSS-PbAMA1-C and Freund’s adjuvant. As a negative control, a group of mice was vaccinated with a single, or
three doses of wild type (WT) starch containing GBSS alone. After immunization, mice were challenged with 10
4 (lethal dose) of P. berghei ANKA strain.
Four independent experiments have been performed (n=4) and P,0.001. (b) Life expectancy of a group of mice immunized by three doses of starch
containing GBSS-PbMSP1-19. Each dose contains 10 mg of purified starch derived GBSS-PbMSP1-19 and Freund’s adjuvant. As a negative control, a group
of mice was vaccinated with three doses of wild type (WT) starch containing GBSS alone. After immunization, the vaccinated mice were challenged with
P. berghei and analyzed as above. Three independent experiments have been performed (n=3) and P,0.05. (c) Life expectancy of a group of mice
vaccinated by three doses of starch containing a mixture of 5 mg of GBSS-PbAMA1-C and 5 mg of GBSS-PbMSP1-19 with Freund’s adjuvant. As a negative
control, a group of mice was also vaccinated with three doses of wild type (WT) starch containing GBSS alone. After vaccination, mice were challenged
with P. berghei and analyzed as above. Three independent experiments have been performed (n=3) and P,0.001. A group of mice were also fed three
times with both starches GBSS-PbAMA1-CandGBSS-PbMSP1-19mixedwith theB-subunit enterotoxin mucosal adjuvant. As a negative control,a groupof
mice was fed with wild type (WT) starch containing GBSS alone. After oral immunization, mice were challenged with 10
4 (lethal dose) of P. berghei and
analyzed as above. n=3 and P,0.001. For all experiments, life expectancy and parasitemia were monitored daily. The panels d, e and f represent
parasitemia profiles corresponding to mice vaccinated and challenged in experiments shown in panels a, b and c, respectively. Data represent mean
values +/2 s.d. and are derived from at least three or four independent experiments with similar results (P,0.001).
doi:10.1371/journal.pone.0015424.g003
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containing GBSS-PbAMA1-C, or GBSS-PbMSP1-19. After immu-
nization, mice were challenged with lethal doses (10
4 infected red
blood cells) of the highly virulent P. berghei ANKA strain. A single
dose of intraperitoneal immunization with starch containing
GBSS-PfAMA1-C showed a significant and reproducible delay of
mortality in P. berghei-challenged mice, compared to mice
immunized with wild type starch GBSS alone (Figure 3a). When
the animals were immunized with three doses of starch containing
GBSS-PbAMA1-C prior to P. berghei challenge, a longer delay in
mortality was observed (Figure 3a). Similarly, mice immunized
with three doses of starch containing GBSS-PbMSP1-19 displayed
significant protection and delay in mortality after parasite
challenge (Figure 3b). Consistent with the delay in mortality,
progression in the proportion of red blood cells infected (%
parasitemia) in immunized and challenged mice was slower in
comparison to control animals (Figure 3d and 3e). Moreover, we
showed that the sera from immunized mice contain specific
immunoglobulins (IgG) generated against the native P. berghei
AMA1 (PbAMA1) using Western blot analyses (Figure 4, panel e).
When mice were simultaneously immunized with both starch
bound GBSS-PbAMA1-C and GBSS-PbMSP1-19, a delay in mice
mortality persisted for a longer period of time (Figure 3c) and
reduction in parasitemia (Figure 3f) was also observed. Interest-
ingly, 25–30% of mice challenged with P. berghei survived
(Figure 3c) after two months post-challenge even though few
infected red blood cells can be visualized (Figure 4, panel c
compare to panels a and b). We confirmed that the remaining
infected red blood cells were not viable parasites because they were
not able to develop any disease symptoms and intra-erythrocytic
development in naive mice. At this time-point, the duration of the
induced protection was also investigated by re-challenging
vaccinated mice with lethal doses of P. berghei. Vaccinated mice
displayed sterile protection, since no infected red blood cells or any
mortality was observed. There was also a significant delay in
mortality when mice were fed purified starch containing both
GBSS-PbAMA1-C and GBSS-PbMSP1-19 (Figure 3c).
Immune sera and purified IgG specific to starch bound
antigen block red blood cell entry by P. falciparum
Humans are the natural host for P. falciparum and the paucity of
animal models for infections with this Plasmodium species makes the
discovery of vaccine candidates challenging. PfMSP1 is a leading
anti-blood stage malaria vaccine candidate [24,25] that undergoes
proteolytic processing duringmerozoitematurationresulting infour
major fragments of 83, 30, 38 and 42 kDa [26]. Before erythrocyte
entry, the 42-kDa fragment undergoes a secondary proteolytic
cleavage, leaving the C-terminal 19-kDa fragment (MSP1-19)
associated with the merozoite [24–26]. Antibodies that are specific
for MSP1-19 in naturally exposed individuals have potent inhibitory
activities against P. falciparum growth in vitro [24]. To explore
whether antibodies elicited by starch-associated antigens could
inhibit in vitro growth of P. falciparum, GBSS-PbMSP1-19 starch was
used to immunize a group of ten mice. Indirect immunofluores-
cence assays were used to demonstrate that antibodies, which were
raised against purified starch containing GBSS-PfMSP1-19 recog-
nizedspecificallyP.falciparummerozoiteswithinmatureschizonts,as
shown by co-localization with the signal of native MSP1 detected
with rabbit specific antibodies (Figure 5a-d). In addition, the anti-
GBSS-PfMSP1-19 antibodies recognized all PfMSP1 processed
products including the major 19-kDa merozoite surface antigen
(Figure 5e-5g). Importantly, anti-GBSS-PfMSP1-19 specific sera
displayed very strong inhibition (circa 95%) of red blood cell
invasion by P. falciparum (Figure 5h). A dose-dependent inhibition of
red blood cell invasion by P. falciparum was also seen with IgG
purified from sera raised against starch-bound GBSS-PfMSP1-19
(Figure S4). Our data indicate that 50% of growth inhibition of P.
falciparum HB3 strain can be achieved with approximately 7+/
20.5 mg/ml (P,0.005) of purified IgG while a weaker inhibition
was observed with the 3D7 strain. These results demonstrate that
the biological activities of the antibodies produced against starch
associated GBSS-PfMSP1-19 can be obtained in a parasite strain-
specific manner [27].
Conclusion
We have engineered high levels of starch-bound GBSS fused to
three distinct malaria vaccine candidates using the unicellular
green algae C. reinhardtii. Our animal vaccine studies suggest that
the levels of transgenic starch antigens that accumulate in the
chloroplast are sufficient to confer substantial protection against
lethal P. berghei in mice. Additionally, the functional activity of
antibodies elicited to P. falciparum was demonstrated by inhibition
of parasite growth in vitro and we ascribed this to blockade of
erythrocyte invasion. C. reinhardtii thus provides an ideal expression
system for the production of recombinant antigens associated with
the starch polysaccharide matrix. In addition, algae can be grown
on scales ranging from a few millilitres to 500,000 liters. Starch
metabolism has been demonstrated to be identical in C. reinhardtii
to that found in vascular plants so that results obtained are likely to
be immediately transposable to crop plants including cereals and
potatoes [28,29]. Aside from the tremendous advantage of
producing clinically relevant antigens in starch, transgenic algae
can also be generated quickly, requiring only a few weeks from the
generation of initial transformants to large scale vaccine
production. These attributes, and the fact that unicellular green
algae fall into the GRAS (Generally Regarded As Safe) category,
make C. reinhardtii a particularly attractive alternative for the
expression of recombinant antigens. Moreover, starch is easy to
purify and represents a protective environment for bound proteins
because GBSS is known to be exceptionally stable with no
detectable loss of activity even after years of storage. In a first
approach to genetically engineering starch particles designated
amylosomes, we have produced recombinant anti-malaria vac-
cines in starch purified from C. reinhardtii. This system should also
be amenable to the production of virtually any recombinant
antigens including vaccine candidates of viruses, bacteria and
other protozoan parasites.
Materials and Methods
Plasmid construction and Chlamydomonas
transformation
The pKB101 vector used to transform Chlamydomonas for
expression of Plasmodium antigens in the chloroplast-starch
compartment is derived from the previously described pMS188
plasmid [30]. The bleomycin resistance gene flanked by MscI and
BamHI restriction sites, which is under the control of chimeric
RBCS2 and HSP70A promoters was replaced by a PCR product
corresponding to a truncated version of the genomic sequence
(STA2) [15], encoding the GBSS protein lacking the 130 C-
terminal amino-acids. The 59 end of this PCR fragment (3 kb) was
cloned blunted while the 39 end was modified by inserting into the
primer both XhoI and BamHI restriction sites. These sites were
used to clone in-frame all Plasmodium synthetic cDNAs designed
based on the codon bias of C. reinhardtii. The AphVIII gene
conferring paromomycin resistance was introduced for efficient
selection of nuclear Chlamydomonas transformants. The AphVIII
gene was obtained by PCR amplification from the pSL18 plasmid
Amylosome as a Novel Vaccine Strategy
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introduced by nuclear transformation using the glass beads
method [32] into the cell wall-less GBSS mutant strain of
Chlamydomonas BafR1 [18]. The transformants were selected on
TAP medium plates [33] supplemented with paromomycin at
10 mg.mL
21. The strains expressing the chimeric proteins were
identified by analyzing the pattern of proteins bound to the starch
granule by SDS-PAGE and Coomassie blue staining.
Electron microscopy, immunofluorescence assays and
immunoblot analyses
For immuno-electron microscopy, the pellets of transformed
and wild type Chlamydomonas were fixed overnight at 4uCi n8 %
paraformaldehyde in PBS buffer, thoroughly washed in the same
buffer and infused in 2.3 M sucrose containing 20% polyvinyl
pyrrolidone 10000 in 0.1 M phosphate buffer. The pellets were
mounted on ultracryotome supports and rapidly frozen in liquid
nitrogen. Ultrathin sections of about 90 nm were obtained and the
grids were incubated with rabbit polyclonal antibodies specific to
P. falciparum MSP1, P. berghei MSP1 (generously supplied by Dr
Tony Holder, Mill Hill, UK) or P. berghei AMA1 (provided by Dr.
Christopher Adda, La Trobe University, Australia). After washing,
the sections were incubated at room temperature for 30 min in the
corresponding secondary gold conjugates (Jackson ImmunoRe-
search Laboratories Inc.). After staining with 0.5% uranyl acetate
in 1.5% methyl cellulose, the sections were observed on a Hitachi
H600 transmission electron microscope.
For immuno-fluorescence assays (IFA), intracellular parasites
were permeabilized with 0.1% Triton X-100 in PBS containing
0.1% glycine (PBS-T) for 10 minutes at room temperature. Samples
were blocked with 3% BSA in PBS-T buffer and mice immune sera
diluted at 1:1000 were added on parasites in the same buffer for one
hour at 37uC. Rabbit secondary antibody coupled to Alexa-488 nm
(MolecularProbes) dilutedat 1:1000 was added inaddition to DAPI
for nucleus staining. For co-localization assay, the rabbit anti-MPS1
serum raised against bacterial expressed recombinant PfMSP1
protein and the goat secondary antibody coupled to Alexa 500 nm
were used at the same dilution. Fluorescence was visualized with a
ZEISS Axiophot microscope.
For immunoblot analyses, total protein extracts from the
synchronized P. falciparum HB3 strain corresponding to ring,
trophozoite or schizont stage, respectively were used. The
asynchronous P. berghei parasitized red blood cells isolated from
mice or purified starch containing GBSS-P. berghei antigens were
also analyzed. The samples were boiled in Laemmli’s buffer,
separated by SDS-PAGE and transferred to Hybond ECL
nitrocellulose (Amersham).
In vitro inhibition of red blood cell entry by P. falciparum
in the presence of immune sera and purified IgG
The P. falciparum HB3 or 3D7 strain was grown in O
+ red blood
cells at 6% hematocrit in RPMI 1640 medium supplemented with
10% of AB
+ human serum. Cultures were maintained at 37uC and
in 90% N2,5 %C O 2,5 %O 2 atmosphere. Synchronized parasites
were obtained by two sorbitol treatments at a 32-hour interval.
Synchronized infected red bloods containing schizonts with 1%
parasitemia at 2% hematocrit using fresh red blood cells were
cultured in complete RPMI medium and invasion assays were
performed as previously described [34]. For standardized growth
inhibition assays (GIA) validated in the Laboratory of Malaria and
Vector Research (NIAID/NIH, USA), IgGs from mice immu-
nized with starch containing GBSS-PfMSP1-19 were purified and
tested as previously described [22].
Mouse immunization with transgenic starch and
P. berghei challenge
Female BALB/c of 6 weeks of age were purchased and kept in
the Pasteur Institute facility. All animals were fed with regular
diet and all procedures were in accordance with national
regulations on animal experimentation and welfare authorized
by the French Ministry of Agriculture and Vetenary committee
(Nu 59-009145). The Pasteur Institute of Lille and the CNRS
review board or ethics committee specifically approved this study.
Figure 4. Starch-bound antigens elicit immune responses and reduce parasitemia after P. berghei challenge. The Giemsa stained thin
smears of red blood cells isolated from mice vaccinated with starch containing wild type GBSS (negative controls), challenged with P. berghei ANKA
and analyzed after 3 weeks post infection. The red arrows indicate that the mice were highly infected with P. berghei (a). The Giemsa stained thin
smears of red blood cells isolated from mice vaccinated with starch containing both GBSS-PbAMA1-C and GBSS-PbMSP1-19, challenged with P. berghei
ANKA and analyzed after 3 weeks post infection (b). The Giemsa stained thin smear of red blood cells isolated from mice vaccinated with starch
containing both GBSS-PbAMA1-C and GBSS-PbMSP1-19, challenged with P. berghei ANKA and analyzed after 6 weeks post-infection (c). Note the
presence of numerous leukocytes (probably neutrophils, green arrows) and fewer infected red blood cells (red arrows) in the vaccinated mice after 3
weeks post-infection (b). Both leukocytes and P. berghei infected red blood cells were not detected in mice, which survived after 6 weeks post-
infection (c). Western blots of total extracts of antigens prepared from red blood cells infected by P. berghei. The immunoblots were incubated with
the immune sera isolated from 4 mice immunized with starch containing wild type GBSS (panel d, lanes 1-4). Blots probed with immune sera of 4
mice immunized with starch containing GBSS-PbAMA1-C (panel e, lanes 1–4). Lane f corresponds to the blots incubated with the positive rabbit
polyclonal antibodies specific to P. berghei AMA1 produced in E. coli.
doi:10.1371/journal.pone.0015424.g004
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complete Freund’s adjuvant and three weeks later were
challenged twice with incomplete adjuvant in two-week intervals
using 10 mg (per mouse) of starch containing GBSS-PbAMA1-C
and/or GBSS-PbMSP1-19 or fed three times with the same
material in the presence of B-subunit of heat-labile enterotoxin
(LTB) from E. coli (Sigma). In some experiments, a single dose of
vaccination was performed. Starch containing wild type GBSS
alone (10 mg per mouse) was used to immunize intraperi-
toneally or orally 10 mice for negative vaccination controls. The
vaccinated mice were challenged with 10,000 red blood cells
parasitized by P. berghei. Parasite growth in vaccinated mice was
monitored by Giemsa-stained thin blood smears, and survival of
mice was assessed daily.
Statistical analysis
Statistical differences between groups of mice used in this study
were evaluated by the Student’s t-test. The Mann-Whitney test
was used for morphometric Giemsa-staining data and the Log
Rank test for survival curves.
Supporting Information
Figure S1 Nucleotide sequences of C. reinhardtii plas-
mid. The plasmid pKB101 was used to clone P. falciparum and P.
berghei genes. This C. reinhardtii expression vector contains the
chimeric RBSC2-HSP70A promoter (nucleotide 796 to 1040),
GBSS genomic DNA sequence deleted at the 3’ end for the 390
last nucleotides (nt 1048 to 4104), blaM Beta-lactamase also
Figure 5. Inhibition of red blood cell entry by P. falciparum. Immunofluorescence assay (IFA) of erythrocyte-containing P. falciparum schizont
with merozoites incubated with a pool of immune sera generated against purified starch GBSS-PfMSP1-19 (b). The nuclei of merozoites were stained
by DAPI (a). The same schizont was also stained with rabbit polyclonal antibodies specific to native MSP1-19 (c). Note the perfect overlap of
fluorescence signals (d, yellow signal), which corresponds to merged pictures in panels a, b and c) of anti-starch GBSS-PfMSP1-19 (b, green signal) and
that of the positive control sera (red, c). The bar represents 5 mm. Western blots of total extract antigens from ring (e), trophozoite (f) and schizont (g)
obtained after synchronization of P. falciparum culture with sorbitol and separated by polyacrylamide gel, transferred to nitrocellulose and probed
with antibodies. Lane 1, a pool of non immune serum used as negative control. Lanes 2 and 3, a pool of immune sera from two independent
experiments in which a group of mice were immunized with starch GBSS-PfMSP1-19. Lane 4 in panel g is from a third independent experiment. The
proteolytically-processed fragments of 83, 42, 38 and 19 kDa derived from the 185–205 kDa PfMSP1 were shown by arrows. (h) Comparison of in vitro
inhibitory effect of immune sera obtained after immunization with starch containing GBSS-PfMSP1-19 with that of immune sera generated against
starch containing wild type GBSS only using the deadly human P. falciparum HB3 strain. Histograms represent mean values +/2 s.d. of separate
experiments (n=3). Results were confirmed in two additional independent experiments (P,0.001).
doi:10.1371/journal.pone.0015424.g005
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(nt 6155 to 6748), AphVIII or paromomycin resistance cassette
(7234-9259).
(TIF)
Figure S2 Parasite nucleotide sequences used for
cloning and expression of P. falciparum MSP1-19, P.
berghei MSP1-19 and P. berghei AMA1-C. The nucleotide
sequences of Plasmodium genes were designed according to the
codon bias of C. reinhardtii.
(TIF)
Figure S3 Longitudinal section of C. reinhardtii cell was
visualized by electron microscopy. The section of C.
reinhardtii cell was probed with polyclonal antibodies specific to
P. berghei AMA1. The algae cell has been transformed by a
construct expressing P. berghei AMA1-C antigen in the starch
localized in the chloroplast. S represents starch grains surrounding
the pyrenoid (P) matrix. The gold particles bind to specific anti-
AMA1 antibodies present on both starch and the pyrenoid matrix.
N, nucleus; C, chloroplast; M, mitochondrion. The bar =500 nm.
(TIF)
Figure S4 P. falciprum strain-specific growth inhibitory
effects in the presence of purified IgGs. A pool of immune
sera of mice vaccinated with starch containing GBSS-PfMSP1-19
was used to purify IgGs. The inhibition of red blood cell invasion
by either P. falciparum HB3 or 3D7 strain was tested in the presence
of purified immune IgGs. Data represent mean values +/- s.d. and
are from at least three independent experiments with two different
pools of immune sera (P,0.005).
(TIF)
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